Pathogenesis of selected multiple primary neoplasms
DOI:
https://doi.org/10.15584/ejcem.2023.3.6Keywords:
pathogenesis, multiple primary neoplasms, multiple primary tumors, oncogenetics, personalized medicine, tumor biologyAbstract
Introduction and aim. Multiple primary tumors are defined as having more than one primary tumor in a different organ location in the same person. Therefore, it is important to know pathogenesis of multiple primary neoplasms to discover new forms of primary prevention and secondary prevention, especially connected with genetic tests which are important for the future of medicine as a part of personalized medicine. The aim of the study is to present selected aspects of the pathogenesis of multiple primary neoplasms.
Material and methods. PubMed databases and Google Scholar were searched.
Analysis of the literature. The rising risk of developing multiple primary cancers is a consequence of the progressive growth and ageing of the population and development of cancer in patients previously treated for cancer. The formation of secondary neoplasms may be multifactorial – to a large extent it is associated with genetic factors that may facilitate neoplastic transformation, for example as a result of radiation therapy, chemotherapy, inherited syndromes, environmental factors such as tobacco or alcohol, sometimes random somatic mutations.
Conclusion. Knowledge of the pathogenesis of multiple primary tumors can contribute to a better understanding of the problem, as well as help in the prevention or early diagnosis of multiple primary tumors (primary and secondary prevention).
Downloads
References
Soerjomataram I, Coebergh JW. Epidemiology of multiple primary cancers. Methods Mol Biol. 2009;471:85-105. doi: 10.1007/978-1-59745-416-2_5
Sakellakis M, Peroukides S, Iconomou G, Boumpoucheropoulos S, Kalofonos H. Multiple primary malignancies: a report of two cases. Chin J Cancer Res. 2014;26(2):215-218.
López GY, Van Ziffle J, Onodera C, et al. The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathol. 2019;137(1):139-150. doi: 10.1007/s00401-018-1906-z
Petru E, Schmähl D. Cytotoxic chemotherapy-induced second primary neoplasms: clinical aspects. Neoplasma. 1991;38(2):147-155.
Capelli D, Menotti D, Fiorentini A, Saraceni F, Olivieri A. Secondary Acute Myeloid Leukemia: Pathogenesis and Treatment. In: Li W. editor. Leukemia. Brisbane (AU): Exon Publications, 2022. doi: 10.36255/exon-publications-leukemia-secondary-acute-myeloid-leukemia
Cheung E, Perissinotti AJ, Bixby DL, et al. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann Hematol. 2019;98(3):541-559. doi: 10.1007/s00277-019-03606-0
Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers. 2022;14(10):2569. doi: 10.3390/cancers14102569
Brown AL, Arroyo VM, Agrusa J, et al. Survival Disparities for Second Primary Malignancies Diagnosed among Childhood Cancer Survivors: A Population-based Assessment. Cancer. 2019;125(20):3623-3630. doi: 10.1002/cncr.32356
Bakkach J, Mansouri M, Loudiyi A, et al. Secondary breast cancer after Hodgkin lymphoma: a case report and literature review. Ecancermedicalscience 2018;12:810. doi: 10.3332/ecancer.2018.810
Shanmugalingam T, Bosco C, Ridley AJ, Van Hemelrijck M. Is there a role for IGF-1 in the development of second primary cancers? Cancer Med. 2016;5(11):3353-3367. doi: 10.1002/cam4.871
Behrens C, Travis LB, Wistuba II, et al. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev. 2000;9(10):1027-1035.
Caldwell BT, Wilcox DT, Cost NG. Current Management for Pediatric Urologic Oncology. Adv Pediatr. 2017;64(1):191-223. doi: 10.1016/j.yapd.2017.04.001
Leslie SW, Sajjad H, Murphy PB. Wilms Tumor. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
MacFarland SP, Duffy KA, Bhatti TR, et al. Diagnosis of Beckwith-Wiedemann syndrome in children presenting with Wilms tumor. Pediatr Blood Cancer. 2018;65(10):e27296. doi: 10.1002/pbc.27296
Sharma D, Subbarao G, Saxena R. Hepatoblastoma. Semin Diagn Pathol. 2017;34(2):192-200. doi: doi: 10.1053/j.semdp.2016.12.015
Finegold MJ, Lopez-Terrada DH, Bowen J, Washington MK, Qualman SJ, College of American Pathologists. Protocol for the examination of specimens from pediatric patients with hepatoblastoma. Arch Pathol Lab Med. 2007;131(4):520-529. doi: 10.5858/2007-131-520-PFTEOS
Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014;26(1):19-28. doi: 10.1097/MOP.0000000000000046
Schnater JM, Kohler SE, Lamers WH, von Schweinitz D, Aronson DC. Where do we stand with hepatoblastoma? A review. Cancer. 2003;98:668-678. doi: 10.1002/cncr.11585
Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 1999;59:269-273.
Petrucelli N, Daly MB, Pal T. BRCA1-and BRCA2-associated hereditary breast and ovarian cancer. GeneReviews®, 2016. Accessed 3 January, 2023.
Van Der Groep P, Van Der Wall E, Van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol. 2011;34(2):71-88. doi: 10.1007/s13402-011-0010-3
Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171-182. doi: 10.1016/S0092-8674(02)00615-3
Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol. 2017;9(8):519-531. doi: 10.1177/1758834017714993
Hodgson A, Turashvili G. Pathology of hereditary breast and ovarian cancer. Front Oncol. 2020;10:531790. doi: 10.3389/fonc.2020.531790
Chow, Laura QM. Head and neck cancer. N Engl J Med. 2020;382(1):60-72. doi: 10.1056/NEJMra1715715
Son E, Panwar A, Mosher CH, Lydiatt D. Cancers of the major salivary gland. J Oncol Pract. 2018;14(2):99-108. doi: 10.1200/JOP.2017.026856
Jiang X, Wu J, Wang J, Huang R. Tobacco and oral squamous cell carcinoma: A review of carcinogenic pathways. Tob Induc Dis. 2019;17:29. doi: 10.18332/tid/105844
Cianfriglia F, Di Gregorio DA, Manieri A. Multiple primary tumours in patients with oral squamous cell carcinoma. Oral Oncol. 1999;35(2):157-163. doi: 10.1016/S1368-8375(98)00105-5
Eberl M, Tanaka LF, Kraywinkel K, Klug SJ. Incidence of Smoking-Related Second Primary Cancers After Lung Cancer in Germany: An Analysis of Nationwide Cancer Registry Data. J Thorac Oncol. 2022;17(3):388-398. doi:10.1016/j.jtho.2021.11.016
Miranda-Galvis M, Loveless R, Kowalski LP, Teng Y. Impacts of Environmental Factors on Head and Neck Cancer Pathogenesis and Progression. Cells. 2021;10:389. doi: 10.3390/cells10020389
Lv M, Zhang X, Shen Y, et al. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. Medicine (Baltimore). 2017;96(17):e6799. doi: 10.1097/MD.0000000000006799
Ratna A, Mandrekar P. Alcohol and Cancer: Mechanisms and Therapies. Biomolecules. 2017;7(3):61. doi: 10.3390/biom7030061
Nieminen MT, Salaspuro M. Local Acetaldehyde-An Essential Role in Alcohol-Related Upper Gastrointestinal Tract Carcinogenesis. Cancers (Basel). 2018;10(1):11. doi:10.3390/cancers10010011
Druesne-Pecollo N, Keita Y, Touvier M, et al. Alcohol drinking and second primary cancer risk in patients with upper aerodigestive tract cancers: a systematic review and meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev. 2014;23(2):324-331. doi:10.1158/1055-9965.EPI-13-0779
Koyanagi YN, Suzuki E, Imoto I, et al. Across-Site Differences in the Mechanism of Alcohol-Induced Digestive Tract Carcinogenesis: An Evaluation by Mediation Analysis. Cancer Res. 2020;80(7):1601-1610. doi: 10.1158/0008-5472.CAN-19-2685
Tamura M, Matsui H, Kaneko T, Hyodo I. Alcohol is an oxidative stressor for gastric epithelial cells: detection of superoxide in living cells. J Clin Biochem Nutr. 2013;53(2):75-80. doi: 10.3164/jcbn.13-32
Strober W, Shishido S, Wood B, Lewis JS, Kuhs K, Ferris RL, Faden DL. Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers. Oral Oncol. 2020;100:104475. doi: 10.1016/j.oraloncology.2019.104475
Copur MS, Manapuram S. Multiple Primary Tumors Over a Lifetime. Oncol. 2019;33(7):629384.
Schaapveld M, Aleman BM, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med. 2015;373(26):2499-2511. doi: 10.1056/NEJMoa1505949
Pobudejska A, Sońta-Jakimczyk D, Pawełczak-Szastok M. Ocena stanu zdrowia i jakości życia osób leczonych w dzieciństwie z powodu ostrej białaczki limfoblastycznej. Pediatr Pol. 2008;83.6:656-661. doi: 10.1016/S0031-3939(08)70190-2
Kawashiri T, Kobayashi D, Uchida M, et al. Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS). J Pharm Pharm Sci. 2021;24:499-508. doi: 10.18433/jpps31862
Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health. 2012;9(7):2444-2453. doi: 10.3390/ijerph9072444
Printz C. Second primary cancers deadlier for younger patients. Cancer. 2017;123(17):3210-3211. doi: 10.1002/cncr.30929
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
